MAI Capital Management RARE — ULTRAGENYX PHARMACEUTICAL IN

Ownership history in MAI Capital Management  ·  5 quarters on record

AI Ownership Summary

MAI Capital Management reported ULTRAGENYX PHARMACEUTICAL IN (RARE) in 5 quarterly 13F filings from 2024 Q4 through 2026 Q1. The latest visible filing shows RARE at 0.00% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this RARE ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was MAI Capital Management's position in ULTRAGENYX PHARMACEUTICAL IN, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

RARE was reported at 0.00% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.0% in 2026 Q1

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q4 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

RARE stock page MAI Capital Management fund profile MAI Capital Management full holdings
How MAI Capital Management held RARE — position size vs. price
% of Fund (quarterly)    RARE price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 5 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 ADDED — — — 8,884 +8,837 +18802.1% 0.00% $186K 2026-05-15 $25.00
2025 Q3 REDUCED 76.5% -34.4% ✅ 47 -153 -76.5% 0.00% $1K 2025-11-10 $31.94
2025 Q2 ADDED — — — 200 +147 +277.4% 0.00% $7K 2025-08-12 $28.11
2025 Q1 UNCHANGED — — — 53 — 0% 0.00% $2K 2025-05-15 $34.84
2024 Q4 INITIATED — — — 53 — — 0.00% $2K 2025-02-14 $42.49

🏢 Other funds also holding RARE

As of 2026 Q1 — sorted by position size

Jones Hill Capital LP 5.23% GordonMD Global Investments LP 4.22% Catalio Capital Management, LP 3.72% Ishara Investments LP 3.46% Eagle Health Investments LP 3Y 3.24% Krensavage Asset Management, LLC 3Y 7Y 3.2% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 2.69% Sofinnova Investments, Inc. 3Y 7Y 2.5% B Group, Inc. 2.1% Palo Alto Investors LP 3Y 7Y 1.91%

FAQ About MAI Capital Management and RARE

These are the practical questions this page is built to answer before you even open the full history table.

How long has MAI Capital Management reported owning RARE?

MAI Capital Management reported RARE across 5 quarterly 13F filings, from 2024 Q4 through 2026 Q1.

What was the largest reported RARE position in MAI Capital Management's portfolio?

The largest reported portfolio weight for RARE was 0.00% in 2026 Q1.

What is the latest reported RARE position on this page?

The most recent filing on this page is 2026 Q1, when MAI Capital Management reported 8,884 shares, equal to 0.00% of portfolio, with an estimated market value of $186K.

What does the chart on this RARE ownership page compare?

The chart compares MAI Capital Management's quarterly RARE portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did MAI Capital Management time their RARE position?

Based on 13F filing dates vs. subsequent RARE price moves, MAI Capital Management correctly timed 2 out of 3 reported position changes (67%). The annualised alpha on RARE relative to SPY over the holding period was -44.7%.

← Back to MAI Capital Management Holdings